We’re reading about Medicare obesity coverage, a 340B analysis
The Biden administration is proposing Medicare and Medicaid coverage for weight loss drugs Wegovy and Zepbound, potentially costing $35 billion over a decade. Amgen’s obesity drug, MariTide, showed promising results with 20% weight loss in a Phase 2 study, leading to questions about its competitiveness. The results suggest MariTide could outperform other drugs like Wegovy…